Events

SHERIDAN, WYOMING – May 8, 2025 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today introduced the Elecsys® PRO-C3 test, a groundbreaking diagnostic solution designed to assess liver fibrosis severity in patients with metabolic dysfunction–associated steatotic liver disease (MASLD). This innovative test, developed in partnership with Nordic Bioscience, provides healthcare providers with a fast and efficient way to evaluate liver fibrosis, a disease that contributes to one in every 25 deaths globally.

The Elecsys PRO-C3 test leverages Roche’s cobas® analyzers, delivering results in just 18 minutes, offering a swift and reliable diagnostic method. This new technology promises to significantly improve patient outcomes by enabling earlier identification of liver fibrosis, particularly in those affected by MASLD, and guiding timely treatment interventions.

SHERIDAN, WYOMING – May 8, 2025 – Roche has announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending an update to the European Union (EU) label for Phesgo®, a subcutaneous (SC) fixed-dose combination of Perjeta® (pertuzumab) and Herceptin® (trastuzumab), used for treating HER2-positive breast cancer. The label update will allow for Phesgo to be administered outside of clinical settings, such as at patients’ homes, under the supervision of a healthcare professional.

This strategic recommendation marks a significant advancement in the delivery of cancer treatments, aligning with patient preferences and improving overall healthcare system efficiency. The move towards at-home administration is expected to reduce the strain on healthcare facilities and is expected to bring substantial cost savings for both patients and healthcare systems.

SHERIDAN, WYOMING – May 8, 2025 – Roche has achieved a significant milestone in oncology diagnostics with the U.S. Food and Drug Administration (FDA) granting Breakthrough Device Designation for its VENTANA® TROP2 (EPR20043) RxDx Device. This marks the first FDA recognition for a computational pathology companion diagnostic (CDx) device using artificial intelligence, highlighting Roche's continued leadership in cancer diagnostics and precision medicine.

The innovative VENTANA TROP2 RxDx device leverages AI to enhance diagnostic precision, improving the detection of non-small cell lung cancer (NSCLC) and enabling personalized treatment decisions. By utilizing cutting-edge digital pathology and AI-driven algorithms, Roche is setting a new standard for oncological diagnostics, advancing both the accuracy and speed of patient treatment strategies.

SHERIDAN, WYOMING – May 8, 2025 – Thermo Fisher Scientific Inc. (NYSE: TMO), a global leader in serving science, has announced that Marc N. Casper, the company’s chairman, president, and chief executive officer, will be presenting at the highly anticipated BofA Securities 2025 Health Care Conference on Tuesday, May 13, 2025, at 11:40 a.m. (ET). The presentation will be available via a live webcast, accessible through the Investors section of Thermo Fisher’s official website.

SHERIDAN, WYOMING – May 8, 2025 – Thermo Fisher Scientific Inc. (NYSE: TMO), a global leader in serving science, has announced a significant $2 billion investment over the next four years, aimed at enhancing U.S. innovation and manufacturing across the life sciences sector. This strategic investment underscores Thermo Fisher's continued confidence in America's ability to lead global scientific advancement while further supporting biopharma companies in the development and production of life-saving medicines.

Strengthening U.S. Manufacturing Infrastructure

The bulk of the $2 billion investment, amounting to $1.5 billion, will be allocated toward expanding and upgrading Thermo Fisher’s U.S.-based manufacturing operations. This move not only solidifies the company's already strong presence in the U.S. but also positions it as a key player in maintaining a resilient healthcare supply chain.

SHERIDAN, WYOMING – May 08, 2025 – Agilent Technologies Inc. (NYSE: A) has introduced its highly anticipated Seahorse XF Flex Analyzer, an advanced, high-performance 24-well system designed to propel metabolic analysis in complex 3D tissue and organoid models. This groundbreaking tool, accompanied by dedicated consumables and kits, promises to transform the way researchers study cellular metabolism, providing critical insights into disease mechanisms and therapeutic development.

Enhancing Metabolic Research Capabilities

Metabolism plays a central role in cellular functions, powering energy production and processes like biosynthesis, mitochondrial function, and cell fate decisions. Disruptions in metabolism are linked to numerous diseases, making metabolic analysis a critical area of research. Traditionally, 2D models have been used for this purpose, but they often fail to reflect the complex biological interactions that occur in living organisms.

SHERIDAN, WYOMING – May 8, 2025 – Agilent Technologies Inc. (NYSE: A) is set to highlight its groundbreaking solutions and strategic collaborations at the upcoming American Association for Cancer Research (AACR) Annual Meeting in Chicago, Illinois, from April 25-30, 2025. Agilent’s innovative products, including advanced DNA cancer panels, multiomic profiling assays, and cutting-edge companion diagnostics, will take center stage, reflecting the company’s commitment to advancing cancer research and therapeutic development.

SHERIDAN, WYOMING – May 8, 2025 – Agilent Technologies Inc. (NYSE: A) has announced that its PD-L1 IHC 22C3 pharmDx (Code SK006) assay has achieved European IVDR certification. This certification positions the assay as a Companion Diagnostic (CDx) to identify gastric or gastroesophageal junction (GEJ) adenocarcinoma patients eligible for treatment with KEYTRUDA® (pembrolizumab), a leading anti-PD-1 therapy developed by Merck. The certification expands the test’s application, offering a significant advancement in cancer treatment options for a growing patient demographic.

SHERIDAN, WYOMING – May 8, 2025 – PerkinElmer, a global leader in analytical instrumentation, is set to showcase two groundbreaking laboratory solutions at Pittcon 2025: the QSight® 500 LC/MS/MS System for high-throughput contaminant analysis and the Spotlight™ Aurora FTIR Microscope for faster material characterization. These innovative systems are designed to boost productivity, enhance accuracy, and improve operational efficiency while helping laboratories meet rigorous regulatory demands and reduce costs.

Advanced Contaminant Detection with QSight® 500 LC/MS/MS System

PerkinElmer’s QSight® 500 LC/MS/MS System is engineered to handle even the most complex sample matrices with exceptional reliability and cost efficiency. The system offers the following advantages:

SHERIDAN, WYOMING – May 8, 2025 – PerkinElmer, a global leader in analytical solutions and specialized services for the bio-pharma, applied, and food markets, has announced its acquisition of Project Farma, a subsidiary of Precision for Medicine. The acquisition, which aims to enhance PerkinElmer's OneSource professional services business, strengthens its position as a critical partner for life sciences organizations looking to accelerate the delivery of innovative therapies.

Strategic Expansion to Support Life Sciences Innovation

The acquisition of Project Farma, a renowned life sciences consultancy, marks a significant milestone in PerkinElmer’s mission to empower customers throughout the value chain. The acquisition broadens OneSource’s lab solutions offering by integrating Project Farma’s extensive experience in advancing technical operations, from initial ideation through to commercialization.

SHERIDAN, WYOMING – May 8, 2025 – Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, has announced its financial results for the first quarter of 2025. Despite navigating a challenging macroeconomic landscape, the company demonstrated solid operational performance, underscoring its commitment to driving growth and margin expansion amidst market volatility.

Financial Performance Overview

For the first quarter of 2025, Bio-Rad reported total net sales of $585.4 million, reflecting a 4.2% decrease from the $610.8 million recorded in Q1 2024. On a currency-neutral basis, the decrease was moderated to 1.5%. This decline was primarily attributed to softer sales in the Life Science segment, compounded by a decrease in academic research funding, particularly in the Americas.

Key Financial Highlights:

SHERIDAN, WYOMING – May 8, 2025 – Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a recognized leader in life science research and clinical diagnostics products, is set to announce its first-quarter financial results for 2025 on Thursday, May 1, 2025. The company will release its earnings after market close, followed by a detailed conference call to discuss the results.

Key Highlights of the Upcoming Report

Bio-Rad, headquartered in Hercules, California, is poised to share insights into its financial performance, reflecting ongoing growth and market leadership in the life sciences sector. The company’s diverse product portfolio spans across research and clinical diagnostics, with an emphasis on innovation and customer success.

SHERIDAN, WYOMING – May 8, 2025 – GN Store Nord A/S has announced a notification under Article 19 of Regulation (EU) No. 596/2014 regarding share transactions carried out by individuals in managerial roles at the company. The transaction was made by Søren Jelert, the company’s Chief Financial Officer (CFO), as part of his regular financial management activities. This report includes details on the purchase of GN Store Nord shares, shedding light on the executive’s commitment to the company and the ongoing market activity surrounding its stock.

Transaction Details

On May 2, 2025, Søren Jelert made a purchase of GN Store Nord shares through Nasdaq Copenhagen. A total of 8,200 shares were acquired in two separate transactions. The shares were purchased at an average price of DKK 90.05 per share, with individual transactions priced at DKK 90.14 and DKK 89.95 for volumes of 4,200 and 4,000 shares, respectively.

SHERIDAN, WYOMING – May 8, 2025 – GN Store Nord A/S has reported its Q1 2025 financial results, highlighting a mix of challenges and opportunities. The company's growth was impacted by market uncertainties, including global macroeconomic pressures and changes in consumer sentiment, particularly in the U.S. Despite these hurdles, GN has initiated proactive cost mitigation strategies aimed at ensuring long-term profitability and supporting margin growth.

Hearing Division Performance: Launch Success Amid Market Challenges

GN's Hearing division experienced a slight decline in organic revenue growth of -1%. While the strong initial uptake of the ReSound Vivia was encouraging, the division faced challenges in the U.S. market and a slowdown in sales from existing products as customers awaited the new launch. Despite these challenges, the positive reception of ReSound Vivia continued into April, positioning the company for expected market share gains.

SHERIDAN, WYOMING – May 8, 2025 – GN Store Nord A/S has announced a series of strategic measures to mitigate the adverse effects of increased tariff levels, recently imposed by the U.S. administration. These proactive actions are designed to protect the company’s EBITA margin for 2025 and secure long-term earnings growth despite the heightened uncertainty in the global trade environment.

As the U.S. tariff rates continue to fluctuate, GN is positioning itself to maintain stability in its financials and minimize disruption to its operations. The company has updated its financial guidance for 2025, outlining the expected impact of tariffs, and is taking decisive steps to adjust its manufacturing strategies, product pricing, and cost management to ensure resilience.

SHERIDAN, WYOMING – May 8, 2025 – In recognition of International Women in Tech Day, GN celebrates the contributions of women who are advancing technology across industries. As a leader in hearing, gaming, and professional audio and video equipment, GN takes pride in showcasing the exceptional women driving innovation in these fields. The day underscores the importance of diversity in the tech sector, highlighting how women’s contributions are shaping products and services that meet diverse needs and drive business growth.

Championing Diversity for Innovation and Impact

At GN, women are not only breaking barriers but also helping to redefine what’s possible in technology. With a focus on continuous innovation, the company’s female leaders share their journeys, emphasizing how their unique perspectives fuel both personal and industry-wide progress.

SHERIDAN, WYOMING – May 8, 2025 – Sennheiser has unveiled its latest innovation, the ACCENTUM Open, a true wireless earbud designed for multitaskers who need both clear sound and awareness of their surroundings. Combining Sennheiser's renowned sound tuning with an open, non-occlusive fit, the ACCENTUM Open provides a simple and efficient way to stay connected to both entertainment and the outside world.

Designed for Modern Multitaskers

The ACCENTUM Open was built with the user’s lifestyle in mind, offering easy-to-use features that enhance productivity and enjoyment. “ACCENTUM Open was designed to complement your busy life—not complicate it,” said Friederike Menking, Product Manager at Sennheiser. “Whether you are listening to music, catching up on a podcast at your desk, or checking in with your friends on your way to the train, the ease of use is second only to the sound.”

SHERIDAN, WYOMING – May 8, 2025 – Hansaton, a leading name in innovative hearing solutions, has unveiled the Hansaton Essenz platform, introducing the first product in the lineup: sound E-R, a cutting-edge receiver-in-canal (RIC) hearing aid. Designed to provide unparalleled sound quality from the very first use, the sound E-R promises exceptional comfort, reliability, and ease of use. Featuring a sleek, modern design and a convenient magnetic charger, this hearing aid is the perfect companion for those on the go or at home.

The Power Behind the Sound E-R: A Groundbreaking Platform

At the heart of the Hansaton Essenz platform are three key components that define the brand’s commitment to quality, performance, and user experience:

SHERIDAN, WYOMING – May 8, 2025 – Cochlear North America has been recognized with the prestigious Silver Award from Cigna's Healthy Workforce Designation for 2024. This esteemed honor reflects the company's ongoing commitment to promoting a supportive and healthy work environment for its employees. With a focus on mental health, physical fitness, and work-life balance, Cochlear North America's wellness initiatives continue to set a benchmark for employee well-being.

Recognition for Employee Wellness Excellence

The Silver Award from Cigna’s Healthy Workforce Designation acknowledges organizations for their comprehensive efforts to support the health and well-being of their workforce. Cochlear North America’s dedication to fostering a thriving workplace is evident in its robust wellness programs, which focus on holistic employee care, including mental health resources, physical fitness initiatives, and a culture that emphasizes work-life balance.

SHERIDAN, WYOMING – May 7, 2025 – Convatec, a global leader in medical technologies focused on chronic condition management, has received regulatory approval for ConvaNiox™, a first-of-its-kind nitric oxide-generating multimodal dressing technology. This innovative product aims to significantly improve outcomes for patients with diabetic foot ulcers (DFUs), offering a powerful solution to an underserved segment of the wound care market.

The full launch of ConvaNiox™ is set for 2026, with an initial rollout scheduled for later this year in key European markets. This new technology combines the potent antimicrobial and antibiofilm properties of nitric oxide to accelerate healing in chronic wounds, particularly DFUs. In clinical trials, ConvaNiox™ demonstrated remarkable results, healing DFUs 60% faster than standard treatments.